Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 3,660,953 | 3,367,324 | 3,215,360 | 2,706,655 | 2,406,908 |
| Cost of Goods | 1,470,983 | 1,362,986 | 1,325,928 | 1,135,615 | 1,041,359 |
| Gross Profit | 2,189,970 | 2,004,338 | 1,889,432 | 1,571,040 | 1,365,549 |
| Operating Expenses | 1,093,825 | 1,106,559 | 958,332 | 877,131 | 813,062 |
| Operating Income | 1,097,128 | 898,765 | 932,028 | 694,524 | 552,846 |
| Interest Expense | 41,581 | 39,858 | 29,808 | 33,125 | 31,055 |
| Other Income | 5,629 | 1,065 | 434 | 586 | 427 |
| Pre-tax Income | 1,061,176 | 859,972 | 902,654 | 661,985 | 522,218 |
| Income Tax | 216,134 | 180,883 | 157,810 | 79,854 | 94,426 |
| Net Income Continuous | 845,042 | 679,089 | 744,844 | 582,131 | 427,792 |
| Minority Interests | N/A | N/A | -1 | 355 | 72 |
| Net Income | $845,042 | $679,089 | $744,845 | $581,776 | $427,720 |
| EPS Basic Total Ops | 10.17 | 8.12 | 8.74 | 6.82 | 4.97 |
| EPS Basic Continuous Ops | 10.17 | 8.12 | 8.74 | 6.82 | 4.97 |
| EPS Diluted Total Ops | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 |
| EPS Diluted Continuous Ops | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 |
| EPS Diluted Before Non-Recurring Items | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 |
| EBITDA(a) | $1,212,036 | $1,010,665 | $1,036,624 | $790,522 | $640,857 |